Dallas Hughes
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$13.0MFederal grants as PI14 awards
2Patents grantedLatest Feb 6, 2024
33Papers4,090 citations
Federal awards and patents by year
AwardsPatents
14 awards · $13.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 6, 2024 | NIH | SBIR Phase II Teixobactin Development for Tuberculosis | $992K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jun 30, 2023 | NIH | SBIR Phase II Teixobactin Development for Tuberculosis | $996K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Aug 29, 2022 | NIH | SBIR Phase II Teixobactin Development for Tuberculosis | $1000K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| May 18, 2022 | NIH | SBIR Phase II Teixobactin Development for Anthrax | $993K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jun 22, 2021 | NIH | SBIR Phase II Teixobactin Development for Anthrax | $996K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jun 15, 2020 | NIH | SBIR Phase II Teixobactin Development for Anthrax | $1000K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Feb 20, 2020 | NIH | SBIR Phase II Preclinical development of teixobactin, a new antibiotic | $1000K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jan 18, 2019 | NIH | SBIR Phase II Preclinical development of teixobactin, a new antibiotic | $997K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Feb 14, 2018 | NIH | SBIR Phase II Preclinical development of teixobactin, a new antibiotic | $999K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| May 17, 2017 | NIH | SBIR Phase II Exploratory Chemistry on a new antibiotic | $738K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jun 13, 2016 | NIH | SBIR Phase II Exploratory Chemistry on a new antibiotic | $746K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Jan 8, 2016 | NIH | SBIR Phase II Preclinical development of teixobactin, a new antibiotic | $741K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Apr 17, 2015 | NIH | SBIR Phase I Selective agents against C. difficile infection | $298K | NOVOBIOTIC PHARMACEUTICALS, LLC |
| Feb 1, 2015 | NIH | SBIR Phase II Preclinical development of teixobactin, a new antibiotic | $1.5M | NOVOBIOTIC PHARMACEUTICALS, LLC |
3 patents as inventor
- US 11203616NOVOBIOTIC PHARMACEUTICALS, LLCDec 21, 2021
- US 11891415NOVOBIOTIC PHARMACEUTICALS, LLCFeb 6, 2024
- US NOVOBIOTIC PHARMACEUTICALS, LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#32
Awards as PI#57
Patents#102
Companies
- NOVOBIOTIC PHARMACEUTICALS, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.